2459 related articles for article (PubMed ID: 22503777)
1. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
2. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
4. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
5. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
8. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.
Wang LS; Leung YY; Chang SK; Leight S; Knapik-Czajka M; Baek Y; Shaw LM; Lee VM; Trojanowski JQ; Clark CM
J Alzheimers Dis; 2012; 31(2):439-45. PubMed ID: 22571982
[TBL] [Abstract][Full Text] [Related]
9. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls.
Struyfs H; Molinuevo JL; Martin JJ; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2014; 41(3):903-9. PubMed ID: 24705548
[TBL] [Abstract][Full Text] [Related]
10. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
12. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N; Andreasson U; Persson S; Arai H; Batish SD; Bernardini S; Bocchio-Chiavetto L; Blankenstein MA; Carrillo MC; Chalbot S; Coart E; Chiasserini D; Cutler N; Dahlfors G; Duller S; Fagan AM; Forlenza O; Frisoni GB; Galasko D; Galimberti D; Hampel H; Handberg A; Heneka MT; Herskovits AZ; Herukka SK; Holtzman DM; Humpel C; Hyman BT; Iqbal K; Jucker M; Kaeser SA; Kaiser E; Kapaki E; Kidd D; Klivenyi P; Knudsen CS; Kummer MP; Lui J; Lladó A; Lewczuk P; Li QX; Martins R; Masters C; McAuliffe J; Mercken M; Moghekar A; Molinuevo JL; Montine TJ; Nowatzke W; O'Brien R; Otto M; Paraskevas GP; Parnetti L; Petersen RC; Prvulovic D; de Reus HP; Rissman RA; Scarpini E; Stefani A; Soininen H; Schröder J; Shaw LM; Skinningsrud A; Skrogstad B; Spreer A; Talib L; Teunissen C; Trojanowski JQ; Tumani H; Umek RM; Van Broeck B; Vanderstichele H; Vecsei L; Verbeek MM; Windisch M; Zhang J; Zetterberg H; Blennow K
Alzheimers Dement; 2011 Jul; 7(4):386-395.e6. PubMed ID: 21784349
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Olsson A; Vanderstichele H; Andreasen N; De Meyer G; Wallin A; Holmberg B; Rosengren L; Vanmechelen E; Blennow K
Clin Chem; 2005 Feb; 51(2):336-45. PubMed ID: 15563479
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
16. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
17. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
18. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
19. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
Dumurgier J; Vercruysse O; Paquet C; Bombois S; Chaulet C; Laplanche JL; Peoc'h K; Schraen S; Pasquier F; Touchon J; Hugon J; Lehmann S; Gabelle A
Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
